NCT03647774View on ClinicalTrials.gov

Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery

PHASE4CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions
Opioid-use Disorder
Interventions
DRUG

Extended release naltrexone

380mg injectable extended release naltrexone every four weeks

Trial Locations (1)

1478

Akershus University Hospital, Loerenskog

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

Hospital of Southern Norway Trust

OTHER

collaborator

The Hospital of Vestfold

OTHER

collaborator

Oslo University Hospital

OTHER

lead

Lars Tanum

OTHER

NCT03647774 - Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery | Biotech Hunter | Biotech Hunter